Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prader-Willi Syndrome Clear all
Recruiting Not applicable Interventional

Regulating Together for Prader-Willi Syndrome: A Group Behavioral Therapy for Emotion Dysregulation

NCT07607730
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Regulating Together group therapy
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
13 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 3 Interventional

The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial

NCT07197034
View directory record Official record
Conditions
Hyperphagia, Prader-Willi Syndrome, Hyperphagia in Prader-Willi Syndrome
Interventions
ARD-101
Drug
Lead sponsor
Aardvark Therapeutics, Inc.
Industry
Eligibility
13 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Orange, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Enrolling by invitation No phase listed Observational

Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome

NCT07450664
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
VYKAT XR
Drug
Lead sponsor
Soleno Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome

NCT05322096
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
RGH-706, Placebo
Drug
Lead sponsor
Gedeon Richter Plc.
Industry
Eligibility
17 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
San Diego, California • Chicago, Illinois • Brooklyn, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Not listed Not applicable Interventional

Family-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home Study

NCT02058342
View directory record Official record
Conditions
Prader Willi Syndrome, Childhood Obesity
Interventions
Active Play at Home
Behavioral
Lead sponsor
California State University, Fullerton
Other
Eligibility
8 Years to 15 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Fullerton, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 9, 2014 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Macronutrient Regulation of Ghrelin and Peptide YY

NCT02464514
View directory record Official record
Conditions
Obesity, Prader Willi Syndrome
Interventions
High carbohydrate meal, High fat meal
Other
Lead sponsor
Duke University
Other
Eligibility
5 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2015 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Results available

Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome

NCT01444898
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Exenatide
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
13 Years to 20 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome

NCT05504395
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
CSTI-500
Drug
Lead sponsor
ConSynance Therapeutics
Industry
Eligibility
13 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome

NCT05783791
View directory record Official record
Conditions
Angelman Syndrome, Prader-Willi Syndrome
Interventions
Newborn Screening Assay
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Not listed
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational

Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA

NCT02109770
View directory record Official record
Conditions
Microdeletion Syndromes, Trisomy 21, Trisomy 18, Trisomy 13, Sex Chromosome Abnormalities
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
Not listed
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
San Carlos, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2019 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood

NCT01852708
View directory record Official record
Conditions
Trisomy 21, Trisomy 18, Trisomy 13, Sex Chromosome Abnormalities, Microdeletion Syndromes
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,059 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
7
States / cities
San Carlos, California • San Gabriel, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Jul 21, 2026, 2:19 PM EDT
Enrolling by invitation Phase 3 Interventional

OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

NCT06420297
View directory record Official record
Conditions
Hyperphagia in Prader-Willi Syndrome
Interventions
Carbetocin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
5 Years to 30 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Orange, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational

Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity

NCT00375089
View directory record Official record
Conditions
Prader-Willi Syndrome, Obesity
Interventions
Group 1, Group 2
Other
Lead sponsor
University of Florida
Other
Eligibility
Up to 60 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
4
States / cities
Orange, California • Gainesville, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2014 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome

NCT05541003
View directory record Official record
Conditions
Prader-Willi Syndrome, Obesity
Interventions
NBT-NM108
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional

B. Lactis B94 Effects of Gastrointestinal Function

NCT03277157
View directory record Official record
Conditions
Quality of Life
Interventions
B. lactis B94, Placebo
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational

Natural History Study of Serious Medical Events in PWS

NCT03718416
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Not listed
Lead sponsor
Foundation for Prader-Willi Research
Other
Eligibility
5 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Walnut, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

NCT05153434
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
ARD-101
Drug
Lead sponsor
Aardvark Therapeutics, Inc.
Industry
Eligibility
17 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Palo Alto, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Jul 21, 2026, 2:19 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Setmelanotide in Patients With Prader-Willi Syndrome

NCT06772597
View directory record Official record
Conditions
Prader-Willi Syndrome, Obesity, Hyperphagia
Interventions
Setmelanotide
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Terminated Phase 3 Interventional

Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome

NCT00603109
View directory record Official record
Conditions
Prader-willi Syndrome
Interventions
rimonabant, placebo
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2023 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Intranasal Oxytocin for Infants With Prader-Willi Syndrome

NCT03245762
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Oxytocin, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
1 Week to 6 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Jul 21, 2026, 2:19 PM EDT
Recruiting Not applicable Interventional

Cerebellar TMS and Satiety in Prader-Willi Syndrome

NCT05938543
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jul 21, 2026, 2:19 PM EDT
Enrolling by invitation Phase 3 Interventional

A Study of Pitolisant in Participants With Prader-Willi Syndrome

NCT07219485
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Pitolisant
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
7 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS

NCT06144645
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
tVNS, intermittent stimulation, tVNS, continuous stimulation
Device
Lead sponsor
Foundation for Prader-Willi Research
Other
Eligibility
10 Years to 40 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
18
States / cities
Palo Alto, California • San Diego, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome

NCT03197662
View directory record Official record
Conditions
Prader-Willi Syndrome, Hyperphagia
Interventions
Intranasal Oxytocin (IN-OXT), Matched Placebo
Drug
Lead sponsor
Eric Hollander
Other
Eligibility
5 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Jul 21, 2026, 2:19 PM EDT